In patients who experience recurring flares of gouty arthritis, long-term chronic management strategies should be implemented to mitigate the incidence of acute attacks.
Lifestyle modification
Weight reduction is recommended for overweight or obese patients [
16], supplemented by an increased intake of selected food types. Patients should be encouraged to include skimmed milk, low-fat yogurt, soy beans, vegetable protein sources, and cherries in their diets, and high-purine foods such as liver, kidney, shellfish, and red meat should be discouraged [
16,
25,
26]. Alcohol consumption <21 units/week for men and <14 units per week for women is also strongly advised—beer, stout, and port should be avoided, and patients should be encouraged to maintain 3 days each week in which alcohol is completely avoided [
16]. Finally, management strategies should also take into account concomitant medications that could increase serum uric acid levels. Thiazide or loop diuretics, low-dose aspirin, cyclosporine, niacin, pyrazinamide, and ethambutol may each cause increased serum uric acid levels [
6].
Pharmacologic management
Patients who experience recurrent acute attacks, arthropathy, tophi, or radiographic changes are candidates for urate-lowering therapy (Table
2) [
14]. The therapeutic goal is to promote crystal dissolution and prevent crystal formation by maintaining serum urate concentrations below the saturation point for MSU [
14,
16].
Table 2
Therapeutic options for chronic hyperuricemia and treatment refractory gouty arthritis
Chronic hyperuricemia | | | | | |
Allopurinola
| Management of patients with signs and symptoms of primary or secondary goutb
| Xanthine oxidase inhibitor | Starting dose of 100 mg/day increasing at 100-mg/day increments each week until sUA ≤ 6 mg/dL | Prophylaxis with colchicine or NSAID to suppress gouty attacks as needed | Contraindicated in patients with history of severe reaction to allopurinol |
| | | Maximum recommended dose = 800 mg/day | Maintain fluid intake to yield daily urine output of ≥2 L | Skin rash can be severe and sometimes fatal |
| | | | Discontinue at the first sign of rash | Other AEs include diarrhea, nausea, and alkaline phosphatase increase |
Febuxostatc
| Chronic management of hyperuricemia in patients with gout | Xanthine oxidase inhibitor | 40 mg OD, increasing to 80 mg OD after 1 week in patients with sUA ≥ 6 mg/dL | Prophylaxis with NSAID or colchicine for up to 6 months recommended to minimize gout flares | Contraindicated in patients receiving azathioprine or mercaptopurine |
| | | | | Cardiovascular thromboembolic events and liver enzyme elevations may be more common |
| | | | | Other AEs include nausea, arthralgia, and rash |
Probenecidd
| Treatment of hyperuricemia associated with gout and gouty arthritis | Uricosuric agent which blocks tubular reabsorption of uric acid | 250 mg BID for 1 week, then 500 mg BID thereaftere
| Alkalization of the urine with sodium bicarbonate (3–7.5 g/day) or potassium citrate (7.5 g/day) recommended | Contraindicated in patients with hypersensitivity to probenecid, children aged <2 years, and is not recommended in patients with known blood dyscrasias or uric acid kidney stones |
| | | | Colchicine or alternative symptomatic therapy advised for patients with exacerbation of gout following therapy | |
Treatment refractory disease | | | | | |
Pegloticasef
| Treatment of chronic gout in adult patients refractory to conventional therapy | Pegylated uricase enzyme | 8 mg as an intravenous infusion every 2 weeks premedicated with antihistamines and corticosteroids; optimal treatment duration not established | Prophylaxis with NSAID or colchicine recommended to minimize gout flares | Black box warning for anaphylaxis and infusion related reactions |
| | | | Discontinue therapy in patients with uric acid levels >6 mg/dLg
| Contraindicated in patients with glucose-6-phosphate dehydrogenase deficiency |
Allopurinol and probenecid have for many years represented the cornerstone of treatment for chronic gouty arthritis. Allopurinol, a xanthine oxidase inhibitor that acts by blocking the production of uric acid through a reduction in purine catabolism, is considered to be an appropriate long-term urate-lowering therapy (Table
2) [
14]. Typical AEs associated with allopurinol include diarrhea, nausea, and increases in alkaline phosphatase, ALT, and AST levels (Allopurinol (tablet); Watson Laboratories, Inc., Corona, CA). Probenecid is a uricosuric agent that increases excretion of uric acid by blocking tubular reabsorption (Table
2) (Probenecid; Watson Pharmaceuticals Inc., Corona, CA). It is used largely as an alternative to allopurinol, although it is considered less efficacious [
14].
Febuxostat is a more recent addition to treatment options for chronic gouty arthritis. It is a nonpurine, xanthine oxidase inhibitor approved for the chronic management of hyperuricemia in patients with gouty arthritis (Table
2) (Uloric® (Febuxostat) tablet for oral use; Takeda Pharmaceuticals America, Inc., Deerfield, IL). Like allopurinol, febuxostat inhibits the synthesis of uric acid by xanthine oxidase. However, animal studies have suggested it provides a more potent and longer-lasting hypouricemic effect compared with allopurinol, an effect attributed to its potent inhibition of both oxidized and reduced forms of xanthine oxidase [
27]. The approval of febuxostat was based on the data from three phase 3 clinical trials, Allopurinol- and Placebo-controlled Efficacy study of febuxostat (APEX) [
28], Febuxostat versus Allopurinol Controlled Trial (FACT) [
29], and CONFIRMS [
30].
The phase 3 clinical studies showed febuxostat (80–240 mg/day) to be significantly more effective than allopurinol (200–300 mg/day). In all studies, the proportion of patients with a urate concentration <6 mg/dL at the end of treatment (the primary end point) was significantly higher among patients receiving febuxostat compared with allopurinol [
28‐
30]. However, it is also noteworthy that these studies did not allow for allopurinol to be dose titrated above 300 mg/day, despite higher doses being recommended for patients with moderately severe tophaceous gout (Allopurinol (tablet); Watson Laboratories, Inc., Corona, CA). In APEX and FACT, prophylaxis against gout flares with naproxen (250 mg twice daily) or colchicine (0.6 mg/day) was administered for the first 8 weeks of treatment, and in both studies the incidence of gout flares was highest during the 4 weeks immediately following withdrawal of prophylaxis [
31]. However, in CONFIRMS, prophylaxis for gout flares was administered for the full 6-month treatment period, and unlike the previous two studies, there was no peak in the incidence of flares at weeks 9–12, but instead a steady decline in the incidence of flares throughout the 6-month treatment period [
32].
Overall, AEs were similar across all treatment groups in these studies [
28‐
30]. In APEX, febuxostat at 240 mg/day was associated with high levels of diarrhea and dizziness, and the incidence of hypertension was also higher in the febuxostat 80-mg/day arm [
28]. Abnormal findings on liver function tests and rash-related AEs were generally similar across treatment arms, and AEs leading to treatment withdrawal were similar in patients receiving febuxostat and allopurinol [
28]. In FACT, the incidence of treatment-related AEs was also similar between treatment arms, with liver function abnormalities, diarrhea, and headache occurring at a similar incidence in each treatment arm. Abnormal liver function tests and rash were the most frequent AEs leading to treatment discontinuation in patients receiving febuxostat [
29]. In CONFIRMS, rash, liver function abnormalities, and diarrhea occurred at broadly similar rates in patients receiving febuxostat or allopurinol [
30]. Premature treatment withdrawal because of an AE was also similar across treatment arms (6.5–8.5%) [
30]. Overall, pooled study data of the most frequently reported AEs for febuxostat and allopurinol showed similar rates of liver function abnormalities (4.6–6.6% vs 4.2%, respectively), nausea (1.1–1.3% vs 0.8%, respectively), arthralgia (0.7–1.1% vs 0.7%, respectively), and rash (0.5–1.6% vs 1.6%, respectively) (Allopurinol (tablet); Watson Laboratories, Inc., Corona, CA).
Treatment of refractory or tophaceous gouty arthritis
Most mammals possess the enzyme urate oxidase that catalyzes the conversion of uric acid to 5-hydroxy isourate and hydrogen peroxide, ultimately leading to the formation of allantoin, which is a more soluble and easily excreted purine metabolite [
33,
34]. However, as a result of mutations to the urate oxidase gene during evolution, this pathway for urate elimination is not functional in humans. Pegloticase is a genetically engineered pegylated mammalian urate oxidase enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy, such as those who have failed to achieve normal serum urate levels or whose symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum tolerated dose (Table
2) (KRYSTEXXA™ (pegloticase) injection, for intravenous infusion; Savient Pharmaceuticals, Inc., East Brunswick, NJ).
In a randomized phase 2 study of 41 patients with gouty arthritis who had been unsuccessfully treated with, or had contraindication to, urate-lowering therapy, pegloticase at doses of 4 or 8 mg every 2 weeks, or 8 or 12 mg every 4 weeks, was associated with a rapid decrease in plasma urate levels to ≤6 mg/dL [
34]. This decrease was seen within 6 h of commencing treatment, and was sustained for the 10-week treatment period in all dose groups, except the 4-mg-every-2-weeks group. Two patients experienced rapid regression of tophi within 12 weeks of starting treatment [
35]. The most commonly reported AEs were nephrolithiasis (15%) and arthralgia (12%), followed by anemia, dyspnea, headache, muscle spasms, nausea, and pyrexia, each reported in 10% of patients. Overall, 76% of patients showed anti-pegloticase immunoreactivity during the study, which was associated with a shortened pegloticase half-life and an increase in urate area under the curve. Among patients who were antibody negative, treatment response was 100% [
34].
Subsequent phase 3 studies have also confirmed the urate-lowering ability of pegloticase in patients with severe gouty arthritis who are refractory or intolerant to allopurinol and with serum urate ≥8 mg/dL [
36]. In two 24-week, randomized, double-blind, placebo-controlled studies, the proportion of patients with plasma urate levels <6 mg/dL for ≥80% of the time during months 3 and 6 (corresponding to the 4-week periods immediately following week 9 and week 21 infusions) was significantly higher in patients receiving pegloticase (8 mg biweekly or every 4 weeks) compared with those receiving placebo (42% and 35% vs 0%,
p < 0.001 for both comparisons). Complete response in one or more tophi (defined as 100% reduction in tophus area) was seen in 40% of patients receiving biweekly pegloticase, 21% of those receiving monthly pegloticase, and 7% of those receiving placebo (biweekly vs placebo,
p = 0.002; monthly vs placebo
p = 0.2). Pegloticase antibodies were present in 134 of 150 treated patients and were significantly associated with an impaired response to therapy and a higher risk of infusion-related reactions. Gout flares (despite prophylaxis with colchicine or NSAIDs throughout the study) and infusion-related reactions (despite pretreatment with fexofenadine, acetaminophen, and hydrocortisone) were the most frequently reported AEs [
36].